Geron (GERN) Total Non-Current Liabilities (2012 - 2026)
Geron's (GERN) quarterly Total Non-Current Liabilities came in at $194.6 million in Q1 2026, up 5.87% year-on-year from $183.8 million in Q1 2025, and down 16.3% quarter-over-quarter from $232.5 million in Q4 2025.
Geron (GERN) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Geron has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $194.6 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $194.6 million, up 5.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $194.6 million (up 5.87% YoY), and the FY2025 annual result was $232.5 million, up 11.24% from the prior year.
- Total Non-Current Liabilities came in at $194.6 million for Q1 2026 at Geron, down from $232.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $232.5 million in Q4 2025 to a low of $183.8 million in Q1 2025.
- The 3-year median for Total Non-Current Liabilities is $201.6 million (2025), against an average of $202.3 million.
- Across the five-year window, Total Non-Current Liabilities advanced 11.24% in 2025 and increased 5.87% in 2026, its largest moves.
- Geron's Total Non-Current Liabilities stood at $209.0 million in 2024, then advanced by 11.24% to $232.5 million in 2025, then retreated by 16.3% to $194.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $194.6 million (Q1 2026), $232.5 million (Q4 2025), and $208.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Geron | 729,618.77 | 729,618.77 | - | 194.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 194.63 Mn |
| Dec 31, 2025 | 232.53 Mn |
| Sep 30, 2025 | 208.63 Mn |
| Jun 30, 2025 | 185.14 Mn |
| Mar 31, 2025 | 183.83 Mn |
| Dec 31, 2024 | 209.04 Mn |
| Dec 31, 2014 | 41.78 Mn |
| Sep 30, 2014 | 7.07 Mn |
| Jun 30, 2014 | 4.47 Mn |
| Mar 31, 2014 | 4.37 Mn |
| Dec 31, 2013 | 7.22 Mn |
| Sep 30, 2013 | 6.58 Mn |
| Jun 30, 2013 | 4.95 Mn |
| Mar 31, 2013 | 6.77 Mn |
| Dec 31, 2012 | 14.10 Mn |